Coronavirus Disease 2019 (COVID-19) Impact on the Sales of Immunology Drugs

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

The global spread of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), throughout 2020 has led to widespread disruption of daily life, leading to national lockdowns in attempts to mitigate the pandemic. Disruptions to healthcare systems and the management of chronic diseases has resulted in patients having difficulty seeing HCPs and receiving treatment, including for autoimmune and inflammatory conditions, especially as many of these immunological disorders require ongoing therapy. Immunological disorders whose treatment has been disrupted include psoriasis, rheumatoid arthritis, inflammatory bowel disease, and others. The key objectives of this report are to: assess the impact of the COVID-19 pandemic on dermatology, gastroenterology, and rheumatology practices; understand how the immunology landscape has changed as a result of the pandemic, and whether these changes are permanent; quantify the impact of the pandemic on sales of key players in the immunology sector; determine how quickly key players will financially recover from the pandemic.

Scope

How patient appointments are conducted.

How treatment selection and administration has been affected.

Whether subsequent waves of infection are expected.

How the sales of key immunology drugs have been affected.

Key Highlights

Assess the impact of the COVID-19 pandemic on dermatology, gastroenterology, and rheumatology practices.

Understand how the immunology landscape has changed as a result of the pandemic, and whether these changes are permanent.

Quantify the impact of the pandemic on sales of key players in the immunology sector.

Determine how quickly key players will financially recover from the pandemic.

Reasons to Buy

The report will enable you to:

Develop business strategies by understanding the trends shaping and driving the immunology market in the US and 5EU.

Drive revenues by understanding the key trends and how companies are reacting during the pandemic in the US and 5EU immunology market.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

Create effective strategies to counter disruption caused by the pandemic in order to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

AbbVie
Almirall
Amgen
Bausch Health
Eli Lilly
Janssen
Johnson & Johnson
Novartis
Pfizer
Regeneron
Roche
Sanofi
Takeda
UCB

Table of Contents

Table of Contents (PowerPoint Deck)

Preface

1.1 Table of Contents

1.2 Abbreviations

1.3 Related Reports

2 Key Findings

3 Background & Methodology

3.1 Background, Objectives, and Scope

3.2 Methodology Overview

3.3 Physician Survey – Respondents Profile

4 Impact of COVID-19 on Patient Appointments

4.1 In-Person Appointments Delayed Due to the Pandemic

4.2 Patient Appointments Moved to Telemedicine

4.3 Newly Diangosed Patients vs. Referred Patients

5 History of Immunology Drugs in Treating COVID-19 Infection

5.1 Anti-IL-6 Biologics

5.2 Anti-TNF Biologics

5.3 JAK Inhibitors

6 Impact of COVID-19 on Prescription Habits

6.1 Pre-pandemic Prescription Habits

6.2 Prescription Habits During the Pandemic (May-Nov 2020)

6.3 Prescription of Biologics vs. Oral Therapies

6.4 Treatment Initiation Delays

6.5 Treatment Delays of Current Therapies

6.6 Expected Rebound of Patient Apppointments and Treatment Initiaitons

7 Expectation for a Subsequent Wave

7.1 Timing and Impact of a Subsequent Wave

8 Impact of COVID-19 on Immunology Drug Sales

8.1 Total Sales of Immunology Drugs in the 6MM, Q1 2020-Q42022

8.2 Certain Drug Classes Suffered During the Pandemic

8.3 Sales of Immunology Drugs Have Been Resilient Despite the Pandemic

8.4 Impact of COVID-19 on the Sales of SC Anti-TNF Biologics Differ Between US and 5EU

8.5 IV Anti-TNF Biologics Struggled During the Initial Outbreak

8.6 Anti-TNF Biosimilars Set to Recover by Q4 2020 from Pandemic Dip

8.7 Future Outlook for IL-5 Biologics Similar in US and 5EU Despite Differing Pandemic Performance

8.8 JAK Inhibitors on a Promising Trajectory in the US and 5EU

9 Appendix

9.1 Bibliography

9.2 Primary Research

9.3 Methodology

9.4 About the Authors

10 Contact Us

Frequently asked questions

Coronavirus Disease 2019 (COVID-19) Impact on the Sales of Immunology Drugs thematic reports
Currency USD
$7,995

Can be used by individual purchaser only

$23,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Coronavirus Disease 2019 (COVID-19) Impact on the Sales of Immunology Drugs was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Coronavirus Disease 2019 (COVID-19) Impact on the Sales of Immunology Drugs in real time.

  • Access a live Coronavirus Disease 2019 (COVID-19) Impact on the Sales of Immunology Drugs dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.